Loading...
NBP logo

NovaBridge BiosciencesNasdaqGM:NBP 주식 보고서

시가총액 US$204.7m
주가
US$1.77
US$8
77.9% 저평가 내재 할인율
1Y78.8%
7D-2.7%
1D
포트폴리오 가치
​
보기

NovaBridge Biosciences

NasdaqGM:NBP 주식 리포트

시가총액: US$204.7m

NovaBridge Biosciences (NBP) 주식 개요

생명공학 회사인 노바브릿지 바이오사이언스는 미국에서 암 치료를 위한 면역항암제를 연구 및 개발하는 기업입니다. 자세히 보기

NBP 펀더멘털 분석
스노우플레이크 점수
가치 평가3/6
미래 성장0/6
과거 실적0/6
재무 건전성6/6
배당0/6

강점

분석가들은 주가가 352% 상승할 것이라는 데 동의합니다.

위험 분석

지난 1년 동안 주주가 크게 희석되었습니다.

수익이 USD$1m 미만입니다($0)

향후 3년 동안 수익이 연평균 20.1% 감소할 것으로 예상됩니다.

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.


NBP Community Fair Values

Create Narrative

See what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

NovaBridge Biosciences 경쟁사

가격 이력 및 성과

NovaBridge Biosciences 주가의 최고가, 최저가 및 변동 요약
과거 주가
현재 주가US$1.77
52주 최고가US$6.79
52주 최저가US$0.99
베타1.56
1개월 변동-27.76%
3개월 변동-44.86%
1년 변동78.79%
3년 변동-43.09%
5년 변동-97.82%
IPO 이후 변동-85.84%

최근 뉴스 및 업데이트

Recent updates

분석 기사 • Dec 31

NovaBridge Biosciences (NASDAQ:NBP) Shares Could Be 41% Below Their Intrinsic Value Estimate

Key Insights Using the 2 Stage Free Cash Flow to Equity, NovaBridge Biosciences fair value estimate is US$6.72...
Seeking Alpha • Oct 14

I-Mab Biopharma Stock: Caution Warranted After Huge Surge

Summary I-Mab stock has surged in 2025 on strong early data for lead asset givastomig in gastric cancer, showing an 83% ORR. Givastomig's results outperformed approved therapies and competitors, fueling optimism amid a large metastatic gastric cancer market and high unmet need. IMAB raised $61.2 million in an August 2025 secondary, securing a cash runway through 2028, with positive analyst sentiment but modest long-term sales projections. Read the full article on Seeking Alpha
Seeking Alpha • Feb 18

I-Mab: Trading Below Net Cash With Multiple Upside Options

Summary I-Mab Biopharma has signed an agreement to divest its assets and business operations in China, becoming a US-based biotech company. The divesting will provide I-Mab with a healthy balance sheet, over $400 million in cash, and the potential to receive up to $80 million in cash consideration from its divested China operation. I-Mab's core assets will consist of three global Immuno-Oncology programs, including uliledlimab, which has shown promising Phase 2 NSCLC clinical trial data. Read the full article on Seeking Alpha
분석 기사 • Feb 08

We're Keeping An Eye On I-Mab's (NASDAQ:IMAB) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Sep 27

I-Mab: Another CD47 Inhibitor Biotech With Great Potential

Summary Clearance from China was received to initiate a phase 3 registrational study using Lemzoparlimab for high-risk MDS patients; trial initiation is expected in Q4 of 2022. Results from phase 2 studies using uliledlimab for the treatment of patients with non-small cell lung cancer are expected in Q4 of 2022. Two other products in the pipeline nearing BLAs in China are felzartamab for multiple myeloma and eftansomatropin alfa for growth hormone deficiency. The global Myelodysplastic Syndrome market is expected to reach $3.26 billion in 2022. I-Mab (IMAB) is a great speculative biotech play to look into. The reason why I state that is because it has a drug known as Lemzoparlimab. The goal is to initiate a phase 3 study using this drug in combination with azacitidine for the treatment of 1st-line myelodysplastic syndrome ((MDS)). The biotech had a great end of phase 2 meeting with Chinese authorities and received the go ahead to initiate a phase 3 study for this program. This late-stage study is expected to be initiated in Q4 of 2022. In addition, the company is also exploring a few other indications with the use of Lemzoparlimab. It has developed a partnership with AbbVie (ABBV) to develop new CD47 antibodies. If such a partnership makes it all the way through all the milestones, then I-Mab would be entitled to receive up to $1.295 billion in milestone payments. The biotech is also in the process of initiating another phase 3 registrational trial as well. This involves the use of its differentiated CD73 antibody uliledlimab being developed to treat patients with non-small cell lung cancer ((NSCLC)). It also has plans to initiate a phase 3 study in the United States targeting other cancer types, however, it hopes to do so through other drugs besides PD-1 inhibitors within the next 12 months. It will also make available results from the ongoing phase 2 study of uliledlimab for the treatment of patients with NSCLC by the end of 2022. The main thing you probably want to know is, what is its intended goal? It believes it could have 5 clinical-stage assets with at least three Biologic Licensing Applications (BLAs) within the next 3 years. Then, it has a bispecific antibody known as TJ-CD4B, which is being developed to treat patients with various types of solid tumors. This drug is currently being explored in a phase 1 study. One key thing to note is that I-Mab is exploring partnership opportunities for uliledlimab and TJ-CD4B, which could also create shareholder value as well. CD47 Inhibitor With Proof Of Concept Already Established The first program to go over involves the use of Lemzoparlimab for the treatment of patients with Myelodysplastic Syndrome. Myelodysplastic Syndrome ((MDS)) involves a group of cancers that keep your blood stem cells from maturing into healthy blood cells. However, MDS can also cause other problems as well, ranging from developing Acute Myeloid Leukemia ((AML)) or anemia (lack of healthy red blood cells to carry oxygen), frequent infections, and bleeding episodes which may not stop. Healthy red blood cells are made in the soft spongy area known as the bone marrow. If such production doesn't work, then red blood cells die in the bone marrow, or if they reach out to parts of your body they die off. When red blood cells die in the bone marrow, there is no room for the healthy red blood cells to exist. This effect leads to serious problems, which is why MDS needs to be taken care of. The global Myelodysplastic Syndrome market is expected to reach $3.26 billion in 2022 and grow at about 9.3% CAGR thereafter until 2030. There are several symptoms that these patients experience as well, which are as follows: You are tired/weak Skin becomes pale Bleed more often Frequent infections Frequent fevers. The goal for I-Mab is to advance Lemzoparlimab to a phase 3 study in treating newly diagnosed higher-risk MDS patients in Q4 of 2022. Of course, it already received authorization from the CDE and NMPA (Chinese authority agencies) to begin such a study. It expects to initiate this phase 3 registrational study before the end of this year, likely Q4 of 2022. The main reason why I'm talking about this program is because it is the furthest along. If a phase 3 study starts by the end of this year for Lemzoparlimab for newly diagnosed MDS patients, then results should be out within a few years. If the trial meets the primary endpoint at completion, then I-Mab holds the potential to have the first CD47 approved in China. That's because, according to talks with Chinese Authorities, this is a registrational trial, which is capable of having a BLA filed should the primary endpoint be met. Thus far, it is a pretty good product in terms of treating patients with hematological malignancies (blood cancers). That is evident by the clinical data achieved to date. About 90 patients with newly diagnosed MDS or acute myeloid leukemia (AML) have received 30 mg/kg Lemzoparlimab in combination with azacitidine (chemotherapy). It was revealed that even without any type of priming dose given to about 50 MDS patients, combination treatment of Lemzoparlimab was very safe/tolerable. It was shown that in terms of MDS patients, there was a >80% objective response rate ((ORR)). With magrolimab and Azacitidine, the combination is comparable to being slightly below this 80% ORR number. Gilead Sciences (GILD) owns magrolimab (CD47 inhibitor) now after buying Forty Seven Inc awhile back. However, I-Mab released updated results at the European Society for Medical Oncology ((ESMO)) Congress 2022 on September 10, 2022 with an oral presentation. For MDS patients receiving a dose of Lemzoparlimab at 3 months, the ORR was 80.6%, and then over 6 months of dosing the ORR rose to 86.7%. The complete response rate in the most recent update was said to be 40%. With this data on hand, it can now push forward to going after high risk MDS patients in the phase 3 study it just received authorization for. Financials According to the 6-K SEC Filing, I-Mab has a cash position of $586 million on hand. It believes that with the current cash on hand, that it could fund its operations for more than 3 years. One thing to keep in mind for this speculative biotech name is that, while its financials are in good order, there is an overhang of an HFCAA delisting. This is not guaranteed, but a possibility because of legislation act holding foreign companies accountable. I believe this is huge risk - as such, I thought it was important to mention this. It should be good on cash for the time being, therefore, I don't see it needing to raise cash in the near-term. I believe what could be possible is if it chooses to raise cash after receiving regulatory approvals in China for one of the BLAs expected in the coming years. Risks To Business There are several risk factors to consider before investing in this biotech. The biggest risk factor would be the overhang of the HFCAA delisting noted above. However, I-Mab states that it has the situation under control by providing shareholders a road map and value to what it intends to do so that it won't be delisted. It believes it can mitigate delisting risks under the HFCAA based on specific steps it has taken in the last 6 months. Despite taking this action, there is still no assurance that it won't face this risk of delisting. It hopes that its current plan of the Statement of Protocol, or a possible contingency plan of changing its auditor should it need to, will accomplish this. The second risk would be with respect to the initiation of the phase 3 registration study, which is using Lemzoparlimab for the treatment of high risk MDS patients. It will take a few years to run this study, and if the primary endpoint is not met, then I-Mab will not be able to file a BLA for approval of this drug in China.
Seeking Alpha • Sep 13

I-Mab gets Chinese nod to start phase 3 combo treatment trial for myelodysplastic syndrome

Chinese biotech I-Mab (NASDAQ:IMAB) on Tuesday said it got local regulatory approval to start a phase 3 trial evaluating its antibody lemzoparlimab in combination with cancer drug azacitidine for the treatment of myelodysplastic syndrome (MDS). MDS is a group of cancers caused due to blood cells that are poorly formed or don't work properly. The approval to start the trial follows a successful completion of an end-of-phase 2 meeting with the Center for Drug Evaluation of China's National Medical Products Administration, IMAB said in a statement. The meeting was supported by results from a phase 2 trial assessing lemzoparlimab in combination with azacitidine for the treatment of patients with newly diagnosed higher-risk MS, IMAB said. The company said it is on track to initiate the late-stage study as planned. U.S.-listed shares of IMAB -4.8% at $5.31 in morning trading.
Seeking Alpha • Aug 30

I-Mab Biopharma Non-GAAP EPADS of -$1.54, revenue of $7.74M

I-Mab Biopharma press release (NASDAQ:IMAB): 1H Non-GAAP EPADS of -$1.54. Revenue of $7.74M (+181.5% Y/Y).
Seeking Alpha • Aug 23

I-Mab and senior executives may buy $40M worth of shares; stock up 10%

I-Mab (NASDAQ:IMAB) and senior management using their own personal funds may purchase up to $40M worth of the company's American Depository Shares on the open market. The buys are part of a share repurchase program previously authorized by the company's board. Shares are up 10% in Tuesday morning trading. See why Seeking Alpha contributor Chris Lacoursiere is bullish on I-Mab (IMAB).
분석 기사 • Aug 20

Newsflash: I-Mab (NASDAQ:IMAB) Analysts Have Been Trimming Their Revenue Forecasts

Today is shaping up negative for I-Mab ( NASDAQ:IMAB ) shareholders, with the analysts delivering a substantial...
Seeking Alpha • Jul 22

I-Mab doses first patient in phase 1 trial of TJ-CD4B in solid tumors in China

I-Mab (NASDAQ:IMAB) said the first patient in China had been treated with its TJ-CD4B in a Phase 1 international multi-center clinical trial for patients with solid tumors, including gastric cancer, gastroesophageal junction carcinoma. TJ-CD4B binds to Claudin 18.2-expressing cancer cells and co-stimulatory molecule 4-1BB on T cells to exert a tumor-killing effect. In March, the U.S. Food and Drug Administration granted Orphan Drug Designation to TJ-CD4B for the treatment of gastric cancer including cancer of gastroesophageal junction.
Seeking Alpha • Jun 23

I-Mab Valuation Offers A Biotech Investment Opportunity

The biotech indices have fallen considerably. Many biotechs are trading with negative enterprise values despite unprecedented innovation in the biotech industry. I-Mab is headed for commercialization with enough cash to carry then into 2025 with multiple products hitting the market. I-Mab shares appear significantly undervalued.
분석 기사 • May 24

Companies Like I-Mab (NASDAQ:IMAB) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • May 06

I-Mab Shaken By Management Moves, Merger Talk And Delisting Threat

There’s no shortage of market-moving news these days about up-and-coming cancer drug maker I-Mab, whose stock is getting pulled every which way as a result. The U.S.-China dispute element was in the headlines this week, when I-Mab’s name was added to a U.S. Securities and Exchange Commission list of 88 Chinese firms that could face potential delisting. According to its 2021 annual report, the company has enough capital to fund its operations through 2025, with $671 million in cash combined with expected milestone payments.
분석 기사 • Apr 01

Bearish: Analysts Just Cut Their I-Mab (NASDAQ:IMAB) Revenue and EPS estimates

The analysts covering I-Mab ( NASDAQ:IMAB ) delivered a dose of negativity to shareholders today, by making a...
Seeking Alpha • Jan 03

I-Mab Founder Retakes Reins In Latest Shakeup Ahead Of Commercialization Phase

Four-year company veteran and CEO Joan Shen to depart I-Mab as chairman and founder Zang Jingwu gets set to resume the role. Analysts upbeat as company earmarks 2023 for regulatory approval of key drugs and launch of production facility. Despite that positive outlook, the company’s shares have gone on a rollercoaster ride since listing at $14 in January 2020.
Seeking Alpha • Oct 14

I-Mab Gets Boost From Latest Industry Signals On New Cancer Treatment

I-Mab's shares surged up to 15% on positive results from a peer developing a similar new type of cancer treatment, though they later gave back most of those gains. Company has plenty of cash on hand and could soon get more as it seeks a deal to commercialize the drug, uliledlimab, with a U.S. or European partner. Despite I-Mab's recent stock price volatility, many are still quite bullish on the company.

주주 수익률

NBPUS BiotechsUS 시장
7D-2.7%1.2%1.1%
1Y78.8%34.6%28.7%

수익률 대 산업: NBP은 지난 1년 동안 34.6%의 수익을 기록한 US Biotechs 산업보다 더 좋은 성과를 냈습니다.

수익률 대 시장: NBP은 지난 1년 동안 28.7%를 기록한 US 시장보다 더 좋은 성과를 냈습니다.

주가 변동성

Is NBP's price volatile compared to industry and market?
NBP volatility
NBP Average Weekly Movement9.8%
Biotechs Industry Average Movement10.8%
Market Average Movement7.2%
10% most volatile stocks in US Market16.5%
10% least volatile stocks in US Market3.1%

안정적인 주가: NBP는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.

시간에 따른 변동성: NBP의 주간 변동성은 지난 1년간 17%에서 10%로 감소했습니다.

회사 소개

설립직원 수CEO웹사이트
201430Sean Funovabridge.com

생명공학 회사인 노바브릿지 바이오사이언스는 미국에서 암 치료를 위한 면역항암제 연구 및 개발에 종사하고 있습니다. 이 회사는 종양학과 안과라는 두 가지 부문으로 운영됩니다. 제품 파이프라인은 위암 및 기타 CLDN18.2 양성 위장관 악성종양 치료를 위해 니볼루맙 및 화학요법과 병용하는 임상 2상 시험 중인 잠재적 CLDN18.2 이중특이항체 기바스토미그(givastomig)와 1차 위암 환자에서 니볼루맙 및 화학요법과 병용하는 임상 1b상 시험으로 구성돼 있습니다.

NovaBridge Biosciences 기초 지표 요약

NovaBridge Biosciences의 순이익과 매출은 시가총액과 어떻게 비교됩니까?
NBP 기초 통계
시가총액US$204.70m
순이익 (TTM)-US$88.34m
매출 (TTM)n/a
0.0x
주가매출비율(P/S)
-2.3x
주가수익비율(P/E)

NBP는 고평가되어 있습니까?

공정 가치 및 평가 분석 보기

순이익 및 매출

최근 실적 보고서(TTM)의 주요 수익성 지표
NBP 손익계산서 (TTM)
매출US$0
매출원가US$0
총이익US$0
기타 비용US$88.34m
순이익-US$88.34m

최근 보고된 실적

Dec 31, 2025

다음 실적 발표일

해당 없음

주당순이익(EPS)-0.76
총이익률0.00%
순이익률0.00%
부채/자본 비율0%

NBP의 장기 실적은 어땠습니까?

과거 실적 및 비교 보기

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/05/24 22:26
종가2026/05/22 00:00
수익2025/12/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

NovaBridge Biosciences는 17명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Bo LiBofA Global Research
Kumaraguru RajaBrookline Capital Markets
Ziyu HeChina International Capital Corporation Limited